Successful treatment of HCV/TB co-infected patient with sofosbuvir and daclatasvir: a case report

被引：3

作者：

Wahid, Braira ^{[1
,2
]}

Saleem, Komal ^{[1
,2
]}

Waqar, Muhammad ^{[1
,2
]}

Wasim, Muhammad ^{[1
,3
]}

Sajjad ^{[1
,4
]}

Idrees, Muhammad ^{[1
,2
,4
,5
]}

机构：

[1] Abdalian Cooperat Soc, Genome Ctr Mol Based Diagnost & Res, Cl-25 Block B Al Sudais Plaza, Lahore, Pakistan

[2] Univ Punjab, CAMB, 87 West Canal Bank Rd Thokar Niaz Baig, Lahore, Pakistan

[3] Khyber Teaching Hosp, Dept Med, Univ Rd, Peshawar, Khyber Pakhtoon, Pakistan

[4] Hazara Univ, Dhodial 2, Mansehra, Khyber Pakhtoon, Pakistan

[5] Univ Punjab, Div Mol Virol & Diagnost, CEMB, 87 West Canal Bank Rd Thokar Niaz Baig, Lahore, Pakistan

来源：

FUTURE VIROLOGY | 2018年 / 13卷 / 05期

关键词：

co-infection; DAA drugs; daclatasvir; interferon; MTB-HCV; relapse; ribavirin; sofosbuvir; SVR; therapeutics; HEPATITIS-C; REACTIVATION;

D O I：

10.2217/fvl-2017-0141

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

This case report suggests proper management of patients co-infected with both HCV and TB. Patients & methods: A 77-year-old female patient visited a primary care physician for a routine follow-up because she had past history of HCV in 2011, but she was successfully treated with interferon-therapy. She experienced HCV relapse in 2016 but did not respond to sofosbuvir and ribavirin and it was later on confirmed that she had TB which made the treatment of HCV more challenging. Results: This is the first evidence that highlights sofosbuvir, daclatasvir and ribavirin as an optimal treatment regimen for patients co-infected with TB. Furthermore, it is necessary to treat TB before initiating HCV treatment because of risk of hepatotoxicity. Conclusion: Co-infection of TB in HCV patients alters treatment response toward nucleotide analog inhibitor, sofosbuvir, an approved anti-HCV drug with high rate of sustained virological response.

引用

页码：317 / 321

页数：5

共 17 条

[1] HEPATOBILIARY TUBERCULOSIS [J].